These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 15339691)

  • 1. Treatment of heparin-induced thrombocytopenia with fondaparinux.
    Harenberg J; Jörg I; Fenyvesi T
    Haematologica; 2004 Aug; 89(8):1017-8. PubMed ID: 15339691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience.
    Grouzi E; Kyriakou E; Panagou I; Spiliotopoulou I
    Clin Appl Thromb Hemost; 2010 Dec; 16(6):663-7. PubMed ID: 19825921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fondaparinux as a treatment option for heparin-induced thrombocytopenia.
    Papadopoulos S; Flynn JD; Lewis DA
    Pharmacotherapy; 2007 Jun; 27(6):921-6. PubMed ID: 17542773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia.
    Efird LE; Kockler DR
    Ann Pharmacother; 2006; 40(7-8):1383-7. PubMed ID: 16788093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparins, low-molecular-weight heparins, and pentasaccharides.
    Dinwoodey DL; Ansell JE
    Clin Geriatr Med; 2006 Feb; 22(1):1-15, vii. PubMed ID: 16377464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fondaparinux cross-reacts with heparin antibodies in vitro in a patient with fondaparinux-related thrombocytopenia.
    Pistulli R; Oberle V; Figulla HR; Yilmaz A; Pfeifer R
    Blood Coagul Fibrinolysis; 2011 Jan; 22(1):76-8. PubMed ID: 21076279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis.
    Alsaleh KA; Al-Nasser SM; Bates SM; Patel A; Warkentin TE; Arnold DM
    Am J Hematol; 2008 Nov; 83(11):876-8. PubMed ID: 18803278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HIT treatment in a cardiac surgery patient.
    Anna N; Boyan T; Kader MA; Catherine M; Matthias K
    Int J Cardiol; 2010 Oct; 144(3):405-7. PubMed ID: 19324432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues.
    Blackmer AB; Oertel MD; Valgus JM
    Ann Pharmacother; 2009 Oct; 43(10):1636-46. PubMed ID: 19737996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT).
    Rota E; Bazzan M; Fantino G
    Thromb Haemost; 2008 Apr; 99(4):779-81. PubMed ID: 18392338
    [No Abstract]   [Full Text] [Related]  

  • 11. Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill.
    Wester JP; Leyte A; Oudemans-van Straaten HM; Bosman RJ; van der Spoel JI; Haak EA; Porcelijn L; Zandstra DF
    Neth J Med; 2007 Mar; 65(3):101-8. PubMed ID: 17387236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic fondaparinux use in a hemodialysis patient with heparin-induced thrombocytopenia type II and extracorporeal circuit thrombosis-a case report and review of the literature.
    Brown P; Jay R; Fox A; Oliver M
    Hemodial Int; 2013 Jul; 17(3):444-9. PubMed ID: 23216938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fondaparinux: does it cause HIT? Can it treat HIT?
    Warkentin TE
    Expert Rev Hematol; 2010 Oct; 3(5):567-81. PubMed ID: 21083474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fondaparinux (Arixtra(R)), a safe alternative for the treatment of patients with heparin-induced thrombocytopenia?
    Badger NO
    J Pharm Pract; 2010 Jun; 23(3):235-8. PubMed ID: 21507819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)--findings from the GerHIT multi-centre registry study.
    Schindewolf M; Steindl J; Beyer-Westendorf J; Schellong S; Dohmen PM; Brachmann J; Madlener K; Pötzsch B; Klamroth R; Hankowitz J; Banik N; Eberle S; Kropff S; Müller MM; Lindhoff-Last E
    Thromb Res; 2014 Jul; 134(1):29-35. PubMed ID: 24703295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fondaparinux treatment in heparin induced thrombocytopenia:a case report].
    Ozsu S; Korkmaz A; Bülbül Y; Oztuna F; Ozlü T
    Tuberk Toraks; 2011; 59(2):178-83. PubMed ID: 21740395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin-induced thrombocytopenia with acute aortic and renal thrombosis in a patient treated with low-molecular-weight heparin.
    Chevalier J; Ducasse E; Dasnoy D; Puppinck P
    Eur J Vasc Endovasc Surg; 2005 Feb; 29(2):209-12. PubMed ID: 15649731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia.
    Lobo B; Finch C; Howard A; Minhas S
    Thromb Haemost; 2008 Jan; 99(1):208-14. PubMed ID: 18217156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fondaparinux: a potential new therapy for HIT.
    Kuo KH; Kovacs MJ
    Hematology; 2005 Aug; 10(4):271-5. PubMed ID: 16085538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of probable bemiparin-induced HIT type II managed with low-dose fondaparinux.
    Koufakis T; Tsapakidis K; Margaritis A; Gabranis I
    J Postgrad Med; 2015; 61(2):109. PubMed ID: 25766343
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.